Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Lisa M C van HoogstratenCalvin C O ManJ Alfred WitjesRichard P MeijerSasja F MulderTineke J SmildeTheodora M RippingLambertus A KiemeneyKatja K H Abennull nullPublished in: World journal of urology (2023)
Guideline adherence regarding NAC use is low and interhospital variation is large, especially for patients with cT2-disease. Although not significant, our data suggest that survival of patients diagnosed in hospitals more inclined to give NAC might be better. Further research is warranted to elucidate the underlying mechanism. As literature clearly shows the potential survival benefit of NAC in patients with cT3-4a disease, better guideline adherence might be pursued.
Keyphrases
- neoadjuvant chemotherapy
- transcription factor
- muscle invasive bladder cancer
- computed tomography
- end stage renal disease
- ejection fraction
- locally advanced
- image quality
- newly diagnosed
- dual energy
- contrast enhanced
- systematic review
- sentinel lymph node
- glycemic control
- healthcare
- prognostic factors
- peritoneal dialysis
- free survival
- positron emission tomography
- big data
- magnetic resonance
- risk assessment
- squamous cell carcinoma
- radiation therapy
- metabolic syndrome